Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections. Net sales break down by activity as follows:
- collaboration services on the methotrexate (70.6%);
- collaboration services on the treatment of macular edema (28.3%);
- other (1.1%).
All sales are in France.
Initial Public Offering